Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CETP | P11597 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | UBE2N | P61088 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932976 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| Hexane SCHEMBL17093132 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL10563903 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL7063457 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL15013420 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL25243382 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL440182 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL325349 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL118392 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL10571108 | 1.00 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295739-A1 | COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES | QUANTEC LIMITED (NZ) | 2025-09-25 | — | — | US | claimed |
| CN-119158061-A | Biodegradable tissue repair functional dressing and preparation method thereof | 修原(辽宁)生物有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-119013037-A | Combination, therapeutic use and prophylactic use | 昆泰克有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-117813075-A | Preservative for cosmetic and pharmaceutical compositions | 赛成公司 | 2024-04-02 | — | — | CN | claimed |
| CN-109069593-B | Combination, therapeutic use and prophylactic use | 昆泰克有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2023153945-A1 | COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES | QUANTEC LIMITED (NZ) | 2023-08-17 | — | — | WO | claimed |
| EP-4106828-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | GIE Medical, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| CN-115461096-A | Polymer encapsulated drug particles | 吉益医疗公司 | 2022-12-09 | — | — | CN | claimed |
| CN-107106663-B | Compositions and kits for enzymatic debridement and methods of use thereof | 罗查尔科技有限责任公司 | 2022-12-06 | — | — | CN | claimed |
| CN-108348452-B | Hydrophilic gels for topical delivery of 5-aminolevulinic acid | 齐默生物科技股份有限公司 | 2022-05-24 | — | — | CN | claimed |
| WO-2009071776-A2 | ANTIMICROBIAL COMPOSITION THAT CAN BE USED IN COSMETICS AND IN DERMATOLOGY | LABORATOIRE NUXE (FR) | 2009-06-11 | — | — | WO | claimed |
| EP-1992327-A1 | Composition based on glycerol ether/polyol mixtures | Air Liquide Santé (International) (FR) | 2008-11-19 | — | — | EP | claimed |
| US-20080255015-A1 | COMPOSITION BASED ON GLYCEROL ETHER/POLYOL MIXTURES | AIR LIQUIDE SANTE (INTERNATIONAL) (FR) | 2008-10-16 | — | — | US | claimed |
| US-7326426-B2 | Compositions and medical devices utilizing bioabsorbable liquid polymers | ETHICON, INC. (US) | 2008-02-05 | — | — | US | claimed |
| EP-1374905-B1 | Injectable microdispersions for medical applications | ETHICON INC (US) | 2007-05-02 | — | — | EP | claimed |
| EP-0747047-B1 | Combination of an antimicrobial compound (e.g. the lipoaminoacid N,n-octanoyl-glycine) and a monoalkylglycerol ether and its use as an antimicrobial agent | ROCHE POSAY LAB PHARMA (FR) | 1998-07-15 | — | — | EP | claimed |
| EP-0747047-A1 | Combination of an antimicrobial compound (e.g. the lipoaminoacid N,n-octanoyl-glycine) and a monoalkylglycerol ether and its use as an antimicrobial agent | LA ROCHE POSAY Laboratoire Pharmaceutique (FR) | 1996-12-11 | — | — | EP | claimed |
| EP-0547727-B1 | Skin and hands composition containing disinfectants and antiseptics | SCHUELKE & MAYR GMBH (DE) | 1996-03-13 | — | — | EP | claimed |
| EP-0547727-A2 | Skin and hands composition containing disinfectants and antiseptics | SCHÀLKE & MAYR GMBH (DE) | 1993-06-23 | — | — | EP | claimed |
| US-4610696-A | Process for the formation of homogeneous fuel compositions containing a petroleum cut and at least one short chain aliphatic alcohol and compositions thereby obtained | ELF FRANCE (FR) | 1986-09-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255015-A1 | COMPOSITION BASED ON GLYCEROL ETHER/POLYOL MIXTURES | MGLL, DAGLA, DAGLB | LMNA 2341/4885CYP2D6 1929/4885SPHK1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.